(Q34371357)

24038993

1 August 2017

title

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program (English)

1 reference

1 August 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

C P Reynolds

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Min H Kang

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Ian Hickson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Malcolm A Smith

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Richard B Lock

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

14

Peter J Houghton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

9

John M Maris

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

13

Raushan T Kurmasheva

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

3

E Anders Kolb

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

6

Stephen T Keir

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1

Hernan Carol

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

12

Dmitry Lyalin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

10

Amy Wozniak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

5

Donya Moradi Manesh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Christopher L Morton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

4 September 2013

1 reference

24038993

1 August 2017

published in

Pediatric Blood Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

245-252

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.

13 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Rational combinations using HDAC inhibitors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Initial testing of aplidin by the pediatric pre-clinical testing program.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

HDAC expression and clinical prognosis in human malignancies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Acetylation of non-histone proteins modulates cellular signalling at multiple levels

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Inhibition of histone deacetylation: a strategy for tumor radiosensitization

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Negative and positive regulation of gene expression by mouse histone deacetylase 1

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Histone acetylation and disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Histone deacetylases, transcriptional control, and cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Role of the histone deacetylase complex in acute promyelocytic leukaemia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Histone acetylation in chromatin structure and transcription

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

6 July 2018

1 reference

A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

21 January 2018

1 reference

JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity

21 January 2018

1 reference

The pediatric preclinical testing program: description of models and early testing results.

21 January 2018

1 reference

Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia

21 January 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

21 January 2018

Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol

27 October 2018

1 reference

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225045

Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24038993

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24038993

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/PBC.24724

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24038993%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

24038993

1 reference